Physician profile
Christopher D Maxwell
NPI 1740278464
$7,014.67
in general payments reported to CMS, 2019-2025
50 companies · $26.18 in 2025
The $26.18 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,652 · 2020: $1,301 · 2021: $1,874 · 2022: $870 · 2023: $792 · 2024: $499 · 2025: $26.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302 · Education: $14.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.49 |
| Education | $14.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $887.54 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $862.69 | 2021-2024 | |
| Novo Nordisk INC | $526.54 | 2019-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $484.58 | 2019-2024 | Stiolto Respimat, Jardiance, Synjardy |
| Lilly USA, LLC | $458.02 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $348.30 | 2019-2023 | |
| Amgen INC. | $310.08 | 2019-2024 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.88 | 2019-2023 | Xifaxan |
| Amarin Pharma, INC. | $172.34 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $168.82 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $165.99 | 2020-2023 | Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $164.75 | 2019-2021 | |
| Astellas Pharma US INC | $161.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $142.28 | 2019-2024 | Trintellix |
| Novartis Pharmaceuticals Corporation | $142.24 | 2019-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Maxwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.